Results 81 to 90 of about 6,478 (160)

Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents. [PDF]

J Am Med Dir Assoc
Khan MA, Daiello LA, Berry SD, Harris DA, Mehta HB, Hsu YS, Leonard CE, McConeghy KW, Zullo AR.   +8 more
europepmc   +1 more source

Deep learning survival analysis with time-varying covariates: extending PyCox to assess COVID-19 antiviral treatments and long-COVID associations. [PDF]

JAMIA Open
Baik SH, Xian H, Baye F, Fung KW, McDonald CJ.   +4 more
europepmc   +1 more source

Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era. [PDF]

ACG Case Rep J
DeBroff J, Abraham J, Yoon BH, Cohen I.
europepmc   +1 more source

Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18-64 Years in Hong Kong: A Population-Based Cohort Study. [PDF]

Clin Drug Investig
Okoli GN, Lin Y, Wu P, Cowling BJ.
europepmc   +1 more source

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population. [PDF]

Med J Aust
Mudrik-Zohar H, Cutfield T, Morpeth S, Hills T, Duffy E, Edwards LJ, Cheng AC, Tong SYC.   +7 more
europepmc   +1 more source

Efficacy and Safety of Nirmatrelvir/Ritonavir and Molnupiravir in Non-Hospitalized Patients with COVID-19: A Single-Center Retrospective Study. [PDF]

Medicina (Kaunas)
Pete M, Lendak D, Kovačević N, Pastornački A, Milovac M, Petrić V.   +5 more
europepmc   +1 more source

Wastewater-Based Genomic Surveillance of SARS-CoV-2 Antiviral Resistance Determinants in Ontario: Towards a Scalable Framework for Population-Level Antiviral Resistance Monitoring. [PDF]

Viruses
Lawal OU, Parreira VR, Overton AK, Knapp JJ, Gibson R, Arts EJ, Zhang L, Rizvi F, Precious M, Charles TC, Goodridge L.   +10 more
europepmc   +1 more source

Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis. [PDF]

J Res Pharm Pract
Khani E, Afsharirad H, Yadegari AT, Zarezadeh M, Asham H, Bannazadeh-Baghi H, Entezari-Maleki T.   +6 more
europepmc   +1 more source

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals. [PDF]

Molecules
Bai X, Ye B, Gao S, Zhan P, Liu X.
europepmc   +1 more source

Decoding Enzyme-Inhibitor Kinetic Mechanisms by Isothermal Titration Calorimetry: The Case of SARS-CoV-2 3CL^pro. [PDF]

Anal Chem
Mazzei L, Ranieri S, Silvestri D, Montelione GT, Ciurli S.   +4 more
europepmc   +1 more source